JonesResearch initiated coverage of Evaxion Biotech (EVAX) with a Buy rating and $10 price target The firm says Evaxion is a clinical-stage company leveraging its AIdriven platform to develop vaccines. The company’s Phase 2 data in melanoma showed a durable clinical benefit and sustained immune response at the two-year cutoff, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Appoints Dr. Helen Tayton-Martin as CEO Amid Strategic Growth
- Evaxion Biotech appoints Tayton-Martin as new CEO
- Evaxion Biotech price target raised to $11 from $6 at Lake Street
- Buy Recommendation for Evaxion Biotech Amid Promising Phase 2 Study Results and Future Potential
- Evaxion Biotech trading resumes